

I hereby certify that this correspondence is being deposited with the United States Postal Service first class mail in an envelope addressed to:

Assistant Commissioner for Patents, Washington, D.C. 20231, on

July 11, 2001

LAW OFFICES OF JONATHAN ALAN QUINE

Richard Pask

Atty Docket No: 407T-894610US


Client Ref: 95-259

7/21/01

TELECENTER 1600/2900

JUL 20 2001

RECEIVED



IN THE UNITED STATES PATENT AND TRADEMARK OFFICE

In re application of:

**SUSAN J. FISHER, OLGA GENBACEV,
RUSSELL FOULK, KARL R. CLAUSER,
and ALMA L. BURLINGAME**
Application No.: 09/101,283

Examiner: S. Houtteman

Art Unit: 1656

Filed: 01/16/1998

For: **ALTERED PROTEIN EXPRESSION
IN HYPOXIC TROPHOBLASTS.**

AMENDMENT

Assistant Commissioner for Patents
Washington, D.C. 20231

Dear Sir:

In response to the Office Action dated January 11, 2001, Applicants respectfully request reconsideration of the above-identified application in view of the following amendments and remarks.

The following documents are enclosed herewith:

- 1) A petition to extend the period of response for three months; and
- 2) A copy of a Revocation and Substitute Power of Attorney.

Please amend the specification and claims as follows

In the Specification.

Delete the paragraphs at page 6, line 23 to page 7, line 4 and insert the following:

--The term "invasiveness", as used herein refers to the ability of a cell to penetrate an extracellular matrix. Methods of measuring invasiveness are well known to those of skill in the art (see, e.g., Librach *et al. J. Cell. Biol.*, 113: 437-449 (1991)). Similarly, an "invasive cell type" or an "invasive cell" refer to a cell capable of penetrating a tissue other than the tissue from which the cell originates. Invasive cells include, but are not limited to trophoblast and malignant cancer cells.

B1